Short answer
Celldex Therapeutics, Inc. (CLDX) filed an 8-K current report with the SEC on April 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). $300.0 million gross equity offering at $29.00 per share.
Celldex Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $300.0 million gross equity offering at $29.00 per share
- 10.345 million shares issued, creating meaningful dilution for existing shareholders
- Approximately $282 million net proceeds available for corporate purposes
- Underwriters hold a 30-day option for 1.55175 million additional shares
- Expected closing around April 6, 2026, subject to customary conditions
Item 8.01 · Other Events
- Celldex launched and priced a securities offering on April 1, 2026
- Offering proceeds expected to fund corporate objectives, subject to closing conditions
- Underwriters hold an option that could increase offering size
- Closing timing and proceeds remain uncertain, creating potential dilution and financing-risk considerations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celldex Therapeutics, Inc. 8-K filings
Get the next CLDX 8-K as it lands
Follow CLDX for push alerts, or ask the research agent what this filing means.